EAM Investors’s Avadel Pharmaceuticals AVDL Stock Holding History

EAM Investors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-34,213	Closed	-$558K	–	309
2015 Q3	$558K	Buy	+34,213	New	+$754K	0.09%	289
2015 Q1	–	Sell	-41,821	Closed	-$716K	–	326
2014 Q4	$716K	Buy	+41,821	New	+$597K	0.1%	301

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

EAM Investors's AVDL Position: Q4 2015 in Review

EAM Investors sold out of Avadel Pharmaceuticals (AVDL) in Q4 2015, closing a stake of 34,213 shares — an estimated $558K sold.

EAM Investors first reported a position in AVDL in Q4 2014 and held it in 2 quarters. The position peaked at $716K in Q4 2014. 89 funds tracked by Wall St. Rank hold AVDL as of Q4 2015.

EAM Investors reported no remaining Avadel Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
EAM Investors sold 34,213 Avadel Pharmaceuticals shares in Q4 2015, an estimated $558K.
EAM Investors first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 2 quarters.
EAM Investors's Avadel Pharmaceuticals position peaked at $716K in Q4 2014.
89 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2015.

Based on EAM Investors's 13F filing for Q4 2015, filed 5 Feb 2016.